B.Riley Financial Thinks Entera Bio’s Stock is Going to Recover

B.Riley Financial analyst Kalpit Patel maintained a Buy rating on Entera Bio (ENTXResearch Report) on January 21 and set a price target of $6.00. The company’s shares closed last Friday at $2.42, close to its 52-week low of $1.22.

According to TipRanks.com, Patel has 0 stars on 0-5 stars ranking scale with an average return of -39.9% and a 3.1% success rate. Patel covers the Healthcare sector, focusing on stocks such as Allogene Therapeutics, Magenta Therapeutics, and Journey Medical Corp.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Entera Bio with a $8.00 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Entera Bio’s market cap is currently $69.66M and has a P/E ratio of -2.86.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of orally delivered large molecule therapeutics. It develops an oral formulation of parathyroid hormone. The company was founded on June 1, 2010 and is headquartered in Jerusalem, Israel.

Read More on ENTX: